Showing results (41-50 of 142) with videos related to

Sort By:
Pageof 15
Haematologica|April 27, 2010
Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myelomaHeinz Ludwig, Zdenek Adam, Elena Tóthová, et al.
Leukemia & Lymphoma|January 7, 2006
Age and hemoglobin level emerge as most important clinical prognostic parameters in patients with osteomyelofibrosis: introduction of a simplified prognostic scoreKathrin Strasser-Weippl, Michael Steurer, Mathias Kees, et al.
European Journal of Haematology|March 13, 2014
Decanucleotide insertion polymorphism of F7 significantly influences the risk of thrombosis in patients with essential thrombocythemiaVeronika Buxhofer-Ausch, Damla Olcaydu, Bettina Gisslinger, et al.
Wiener Klinische Wochenschrift|March 29, 2013
Experience with lenalidomide in an Austrian non-study population with advanced myelofibrosisSonja Burgstaller, Michael Fridrik, Sabine Hojas, et al.
Blood|November 7, 2007
Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disordersDaniela Pietra, Sai Li, Angela Brisci, et al.
European Journal of Haematology|September 10, 2020
Impact of platelets on major thrombosis in patients with a normal white blood cell count in essential thrombocythemiaVeronika Buxhofer-Ausch, Dominik Wolf, Siegfried Sormann, et al.
European Journal of Haematology|February 14, 2004
Long-term follow up of patients with multiple myeloma after high-dose chemotherapy and allogeneic stem cell transplantationWerner Rabitsch, Erika Prinz, Jutta Ackermann, et al.
Journal of Cancer Research and Clinical Oncology|July 20, 2020
Elotuzumab, pomalidomide, and dexamethasone is a very well tolerated regimen associated with durable remission even in very advanced myeloma: a retrospective study from two academic centersDorothea Hose, Martin Schreder, Jochen Hefner, et al.
Cancers|July 29, 2025
Optimizing Belantamab Mafodotin in Relapsed or Refractory Multiple Myeloma: Impact of Dose Modifications on Adverse Events and Hematologic Response in a Real-World Retrospective StudyLina Zoe Rüsing, Jakob Schweighofer, Julia Aschauer, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|November 5, 2011
Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasmsGregor Hoermann, Sabine Cerny-Reiterer, Harald Herrmann, et al.
Pageof 15